Full text is available at the source.
Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide
Simulated blood sugar and weight loss changes when switching weekly diabetes medication from semaglutide or dulaglutide to tirzepatide
AI simplified
Abstract
Predicted reductions in HbA1c after switching to tirzepatide could be between 1.95% and 2.46% by Week 66.
- Model simulations indicated that mean HbA1c decreases for semaglutide ranged from 1.22% to 1.79% at Week 26.
- Mean body weight loss for semaglutide at Week 26 was predicted to be between 3.62 kg and 6.87 kg.
- Dulaglutide was associated with mean HbA1c decreases of 1.53% to 1.84% and body weight loss of 2.55 kg to 3.71 kg at Week 26.
- Switching to tirzepatide may lead to body weight reductions of 6.50 kg to 12.1 kg by Week 66.
- The model suggests that even the lowest dose of tirzepatide could enhance reductions in HbA1c and body weight compared to current treatments.
AI simplified